Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Blood Protein Disorders × ricolinostat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms by Histologic Type 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Fallopian Tube Neoplasms 1 Blood Protein Disorders 1

Interventions

ricolinostat 1 pomalidomide 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated

103 enrolled 21 charts

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡